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Abstract
The gut–brain axis refers to the bidirectional communication between the enteric nervous system and the central nervous system.Mounting evidence supports
the premise that the intestinalmicrobiota plays a pivotal role in its function andhas led to themore common and perhapsmore accurate termgut–microbiota–brain
axis. Numerous studies have identified associations between an altered microbiome and neuroimmune and neuroinflammatory diseases. In most cases, it is
unknown if these associations are cause or effect; notwithstanding, maintaining or restoring homeostasis of the microbiota may represent future opportunities
when treating or preventing these diseases. In recent years, several studies have identified the diet as a primary contributing factor in shaping the composition of the
gut microbiota and, in turn, the mucosal and systemic immune systems. In this review, we will discuss the potential opportunities and challenges with respect to
modifying and shaping the microbiota through diet and nutrition in order to treat or prevent neuroimmune and neuroinflammatory disease.
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